Addex Therapeutics (ADXN) Non Operating Income: 2022-2024
Historic Non Operating Income for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $76.9 billion.
- Addex Therapeutics' Non Operating Income rose 160.83% to $76.9 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$854.8 million, marking a year-over-year increase of 65.06%. This contributed to the annual value of $26,199 for FY2024, which is 109.15% up from last year.
- As of Q4 2024, Addex Therapeutics' Non Operating Income stood at $76.9 billion, which was up 198.90% from -$77.8 billion recorded in Q3 2024.
- Addex Therapeutics' Non Operating Income's 5-year high stood at $166.1 billion during Q2 2023, with a 5-year trough of -$126.5 billion in Q4 2023.
- In the last 3 years, Addex Therapeutics' Non Operating Income had a median value of -$53,218 in 2023 and averaged -$275.1 million.
- The largest annual percentage gain for Addex Therapeutics' Non Operating Income in the last 5 years was 184,658,580.45% (2023), contrasted with its biggest fall of 44,838,276.07% (2023).
- Quarterly analysis of 3 years shows Addex Therapeutics' Non Operating Income stood at -$282,031 in 2022, then plummeted by 44,838,276.07% to -$126.5 billion in 2023, then skyrocketed by 160.83% to $76.9 billion in 2024.
- Its last three reported values are $76.9 billion in Q4 2024, -$77.8 billion for Q3 2024, and -$117,489 during Q2 2024.